The US Department of Commerce's Bureau of Industry and Security added 32 new entities to its Entity List, notably including three Chinese biotechnology companies: Beijing Tianyi Huiyuan Biotechnology, Beijing Tsingke Biotech, and Sangon Biotech (Shanghai). These firms are accused of posing significant risks of diverting US-origin items to Chinese military medical research institutes, leading to stringent US export license requirements under a presumption of denial. This regulatory move intensifies technology and trade tensions amid ongoing US-China dialogues.